Literature DB >> 16452658

Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice.

Michael T Heneka1, Mutiah Ramanathan, Andreas H Jacobs, Lucia Dumitrescu-Ozimek, Andras Bilkei-Gorzo, Thomas Debeir, Magdalena Sastre, Norbert Galldiks, Andreas Zimmer, Mathias Hoehn, Wolf-Dieter Heiss, Thomas Klockgether, Matthias Staufenbiel.   

Abstract

Locus ceruleus (LC) degeneration and loss of cortical noradrenergic innervation occur early in Alzheimer's disease (AD). Although this has been known for several decades, the contribution of LC degeneration to AD pathogenesis remains unclear. We induced LC degeneration with N-(2-chloroethyl)-N-ethyl-bromo-benzylamine (dsp4) in amyloid precursor protein 23 (APP23) transgenic mice with a low amyloid load. Then 6 months later the LC projection areas showed a robust elevation of glial inflammation along with augmented amyloid plaque deposits. Moreover, neurodegeneration and neuronal loss significantly increased. Importantly, the paraventricular thalamus, a nonprojection area, remained unaffected. Radial arm maze and social partner recognition tests revealed increased memory deficits while high-resolution magnetic resonance imaging-guided micro-positron emission tomography demonstrated reduced cerebral glucose metabolism, disturbed neuronal integrity, and attenuated acetylcholinesterase activity. Nontransgenic mice with LC degeneration were devoid of these alterations. Our data demonstrate that the degeneration of LC affects morphology, metabolism, and function of amyloid plaque-containing higher brain regions in APP23 mice. We postulate that LC degeneration substantially contributes to AD development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16452658      PMCID: PMC6675491          DOI: 10.1523/JNEUROSCI.4236-05.2006

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  51 in total

1.  Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice.

Authors:  P F Chapman; G L White; M W Jones; D Cooper-Blacketer; V J Marshall; M Irizarry; L Younkin; M A Good; T V Bliss; B T Hyman; S G Younkin; K K Hsiao
Journal:  Nat Neurosci       Date:  1999-03       Impact factor: 24.884

2.  Effects of central noradrenaline depletion by the selective neurotoxin DSP-4 on the behaviour of the isolated rat in the elevated plus maze and water maze.

Authors:  M D Lapiz; Y Mateo; S Durkin; T Parker; C A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2001-05       Impact factor: 4.530

Review 3.  Inflammation and Alzheimer's disease.

Authors:  H Akiyama; S Barger; S Barnum; B Bradt; J Bauer; G M Cole; N R Cooper; P Eikelenboom; M Emmerling; B L Fiebich; C E Finch; S Frautschy; W S Griffin; H Hampel; M Hull; G Landreth; L Lue; R Mrak; I R Mackenzie; P L McGeer; M K O'Banion; J Pachter; G Pasinetti; C Plata-Salaman; J Rogers; R Rydel; Y Shen; W Streit; R Strohmeyer; I Tooyoma; F L Van Muiswinkel; R Veerhuis; D Walker; S Webster; B Wegrzyniak; G Wenk; T Wyss-Coray
Journal:  Neurobiol Aging       Date:  2000 May-Jun       Impact factor: 4.673

4.  Dose-dependent effects of noradrenergic denervation by DSP-4 treatment on forced swimming and beta-adrenoceptor binding in the rat.

Authors:  J Harro; R Pähkla; M Harro; A Kask; L Oreland
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

5.  A nerve growth factor mimetic TrkA antagonist causes withdrawal of cortical cholinergic boutons in the adult rat.

Authors:  T Debeir; H U Saragovi; A C Cuello
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

6.  Reorganization of cholinergic terminals in the cerebral cortex and hippocampus in transgenic mice carrying mutated presenilin-1 and amyloid precursor protein transgenes.

Authors:  T P Wong; T Debeir; K Duff; A C Cuello
Journal:  J Neurosci       Date:  1999-04-01       Impact factor: 6.167

7.  Amyloid-associated neuron loss and gliogenesis in the neocortex of amyloid precursor protein transgenic mice.

Authors:  Luca Bondolfi; Michael Calhoun; Florian Ermini; H Georg Kuhn; Karl-Heinz Wiederhold; Lary Walker; Matthias Staufenbiel; Mathias Jucker
Journal:  J Neurosci       Date:  2002-01-15       Impact factor: 6.167

8.  Noradrenergic changes, aggressive behavior, and cognition in patients with dementia.

Authors:  Kim L Matthews; Christopher P L-H Chen; Margaret M Esiri; Janet Keene; Stephen L Minger; Paul T Francis
Journal:  Biol Psychiatry       Date:  2002-03-01       Impact factor: 13.382

9.  Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer's disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology.

Authors:  H J Lüth; M Holzer; U Gärtner; M Staufenbiel; T Arendt
Journal:  Brain Res       Date:  2001-09-14       Impact factor: 3.252

10.  Norepinephrine promotes long-term potentiation in the adult rat hippocampus in vitro.

Authors:  Y Izumi; C F Zorumski
Journal:  Synapse       Date:  1999-03-01       Impact factor: 2.562

View more
  115 in total

1.  Increased regional cerebral glucose uptake in an APP/PS1 model of Alzheimer's disease.

Authors:  Géraldine Poisnel; Anne-Sophie Hérard; Nadine El Tannir El Tayara; Emmanuel Bourrin; Andreas Volk; Frank Kober; Benoit Delatour; Thierry Delzescaux; Thomas Debeir; Thomas Rooney; Jésus Benavides; Philippe Hantraye; Marc Dhenain
Journal:  Neurobiol Aging       Date:  2011-11-12       Impact factor: 4.673

Review 2.  APP transgenic mice for modelling behavioural and psychological symptoms of dementia (BPSD).

Authors:  R Lalonde; K Fukuchi; C Strazielle
Journal:  Neurosci Biobehav Rev       Date:  2012-02-21       Impact factor: 8.989

3.  Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine.

Authors:  Michael T Heneka; Fabian Nadrigny; Tommy Regen; Ana Martinez-Hernandez; Lucia Dumitrescu-Ozimek; Dick Terwel; Daniel Jardanhazi-Kurutz; Jochen Walter; Frank Kirchhoff; Uwe-Karsten Hanisch; Markus P Kummer
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

4.  Modulation of neuroinflammation and pathology in the 5XFAD mouse model of Alzheimer's disease using a biased and selective beta-1 adrenergic receptor partial agonist.

Authors:  Pooneh Memar Ardestani; Andrew K Evans; Bitna Yi; Tiffany Nguyen; Laurence Coutellier; Mehrdad Shamloo
Journal:  Neuropharmacology       Date:  2017-01-13       Impact factor: 5.250

5.  Effects of DSP4 on the noradrenergic phenotypes and its potential molecular mechanisms in SH-SY5Y cells.

Authors:  Yan Wang; Phillip R Musich; Moises A Serrano; Yue Zou; Jia Zhang; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2013-08-31       Impact factor: 3.911

6.  Neurotoxin-induced DNA damage is persistent in SH-SY5Y cells and LC neurons.

Authors:  Yan Wang; Phillip R Musich; Kui Cui; Yue Zou; Meng-Yang Zhu
Journal:  Neurotox Res       Date:  2015-03-01       Impact factor: 3.911

7.  Amyloid beta peptide-(1-42) induces internalization and degradation of beta2 adrenergic receptors in prefrontal cortical neurons.

Authors:  Dayong Wang; Eunice Y Yuen; Yuan Zhou; Zhen Yan; Yang K Xiang
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

8.  A noradrenergic lesion exacerbates neurodegeneration in a Down syndrome mouse model.

Authors:  Jason Lockrow; Heather Boger; Greg Gerhardt; Gary Aston-Jones; David Bachman; Ann-Charlotte Granholm
Journal:  J Alzheimers Dis       Date:  2011       Impact factor: 4.472

9.  Spatial learning impairments in PLB1Triple knock-in Alzheimer mice are task-specific and age-dependent.

Authors:  D Ryan; D Koss; E Porcu; H Woodcock; L Robinson; B Platt; G Riedel
Journal:  Cell Mol Life Sci       Date:  2013-03-28       Impact factor: 9.261

Review 10.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.